Cost-effectiveness of childhood hepatitis A vaccination in Argentina: A second dose is warranted

Revista Panamericana de Salud Publica/Pan American Journal of Public Health

Volumn 21, Issue 6, 2007, Pages 345-356

  Ellis, Alejandro ^a   Rüttimann, Ricardo W ^b   Jacobs, R Jake ^c   Meyerhoff, Allen S ^c   Innis, Bruce L ^d  

^a Government of the City of Buenos Aires   (Argentina)

^b GlaxoSmithKline   (Argentina)

^c Capitol Outcomes Research Inc   (United States)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Argentina; Costs and cost analysis; Hepatitis A; Immunization schedule; Quality adjusted life years; Vaccination

Indexed keywords

CHILD HEALTH; COST-BENEFIT ANALYSIS; HEALTH CARE; HEPATITIS; IMMUNIZATION; VACCINATION;

ARGENTINA; SOUTH AMERICA;

HEPATITIS A VACCINE;

ADOLESCENT; ADULT; AGE; ARGENTINA; ARTICLE; CHILD; COHORT ANALYSIS; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS; EVALUATION; HEPATITIS A; HUMAN; IMMUNIZATION; INCIDENCE; INFANT; MIDDLE AGED; PRESCHOOL CHILD; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; VACCINATION;

ADOLESCENT; ADULT; AGE FACTORS; ARGENTINA; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COST-BENEFIT ANALYSIS; HEPATITIS A; HEPATITIS A VACCINES; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; INCIDENCE; INFANT; MARKOV CHAINS; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; VACCINATION;

EID: 35448963853     PISSN: 10204989     EISSN: 16805348     Source Type: Journal    
DOI: 10.1590/S1020-49892007000500002     Document Type: Article

References (52)

1. Ciocca M. Clinical course and consequences of hepatitis A infection. Vaccine. 2000;18 (Suppl 1):S71-4.
2. Centeno MA, Bes DF, Sasbon JS. Mortality risk factors of a pediatric population with fulminant hepatic failure undergoing orthotopic liver transplantation in a pediatric intensive care unit. Pediatr Crit Care Med. 2002;3(3): 227-33.
3. Williams E, Questa H, Wacholder V, Rojas L, Cervio G, Bianco G, et al. Development of a pediatric liver transplantation program in Argentina. Pediatr Surg Int. 1998;13(5-6):319-22.
4. Armstrong GL, Bell BP. Hepatitis A virus infections in the United States: model-based estimates and implications for childhood immunization. Pediatrics. 2002;109(5):839-45.
5. Berge JJ, Drennan DP, Jacobs RJ, Jakins A, Meyerhoff AS, Stubblefield W, et al. The cost of hepatitis A infections in American adolescents and adults in 1997. Hepatology. 2000;31(2):469-73.
6. Tanno H, Fay OH, Rojman JA, Palazzi J. Biphasic form of hepatitis A virus infection: a frequent variant in Argentina. Liver. 1988; 8(1):53-7.
7. Lemon SM. Type A viral hepatitis. New developments in an old disease. N Engl J Med. 1985;313(17):1059-67.
8. Mathur P, Arora NK. Considerations of HAV vaccine in India. Indian J Pediatr. 1999;66(1): 111-20.
9. Tanaka J. Hepatitis A shifting epidemiology in Latin America. Vaccine. 2000;18 (Suppl 1): S57-60.
10. Tapia-Conyer R, Santos JI, Cavalcanti AM, Urdaneta E, Rivera L, Manterola A, et al. Hepatitis A in Latin America: a changing epidemiologic pattern. Am J Trop Med Hyg. 1999;61(5):825-9.
11. Valenzuela MT, Jacobs RJ, Arteaga O, Navarrete MS, Meyerhoff AS, Innis BL. Cost-effectiveness of universal childhood hepatitis A vaccination in Chile. Vaccine. 2005;23(32): 4110-9.
12. Novoa J, Caillou E. Hepatitis A in a pediatric population from northwestern Argentina. Acta Gastroenterol Latinoam. 1998;28(2): 213-8.
13. Innis BL, Snitbhan R, Kunasol P, Laorakpongse T, Poopatanakool W, Kozik CA, et al. Protection against hepatitis A by an inactivated vaccine. JAMA 1994;271(17):1328-34.
14. Van Herck K, Van Damme P, Lievens M, Stoffel M. Hepatitis A vaccine: indirect evidence of immune memory 12 years after the primary course. J Med Virol. 2004;72(2):194-6.
15. Wiedermann G, Kundi M, Ambrosch F. Estimated persistence of anti-HAV antibodies after single dose and booster hepatitis A vaccination (0-6 schedule). Acta Trop. 1998;69(2): 121-5.
16. Ginsberg GM, Slater PE, Shouval D. Cost-benefit analysis of a nationwide infant immunization programme against hepatitis A in an area of intermediate endemicity. J Hepatol. 2001;34(1):92-99.
17. Jacobs RJ, Greenberg DP, Koff RS, Saab S, Meyerhoff AS. Regional variation in the cost effectiveness of childhood hepatitis A immunization. Pediatr Infect Dis J. 2003;22(10): 904-14.
18. Navas E, Salleras L, Gisbert R, Dominguez A, Bruguera M, Rodríguez G, et al. Efficiency of the incorporation of the hepatitis A vaccine as a combined A+B vaccine to the hepatitis B vaccination programme of preadolescents in schools. Vaccine. 2005;23(17-18):2185-9.
19. Szucs T. Cost effectiveness of hepatitis A and B vaccination programme in Germany. Vaccine. 2000;18(Suppl 1):S86-9.
20. MacIntyre CR, Burgess MA, Hull B, McIntyre PB. Hepatitis A vaccination options for Australia. J Paediatr Child Health. 2003;39(2):83-7.
21. Soogarun S, Wiwanitkit V. Vaccinating Thai adolescents against hepatitis A: is it cost-effective? Southeast Asian J Trop Med Public Health. 2002;33(Suppl 3):145-8.
22. Argentina, Ministerio de Salud y Ambiente. Resolución 653/05. Boletín Oficial de la República Argentina. 113(30677). 13 June 2005. Buenos Aires.
23. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics. 1998;13(4):397-409.
24. Pérez CA, Oviedo JJ, González ML, Ortíz PO. The evaluation of acute viral hepatitis seen in a regional hospital. Acta Gastroenterol Latinoam. 1992;22(4):239-42.
25. Argentina, Instituto Nacional de Estadística y Censos. Novedades. Available from: http://www.indec.mecon.ar. Accessed 12 February 2005.
26. Lepetic A, Dayán G, Carnevale H, Macchi A, Sturba E, Stamboulian D. Seroprevalence of hepatitis A in Argentine travelers: an economic evaluation of different preventive strategies [conference presentation]. International Congress on Infectious Diseases, Buenos Aires, Argentina, 2000.
27. Aguilar PG, de Wouters L, Isida S, Martorano A, Ruttimann R. Protección contra hepatitis A en la adolesencia: asociación de seroprevalencia y antecedentes clínico-epidemiológicos. Arch Argent Pediatr. 2003;101(2):93-8.
28. López H, Zitto T, Bare P, Vidal G, Vukasovic J, Gómez R. Prevalence of anti-hepatitis A antibodies in an urban middle class area of Argentina: some associated factors. Int J Infect Dis. 2000;4(1):34-7.
29. Xifró MC, Contrini MM, De Rosa MF, Lavarias S, Teplitz E, Palla ME, et al. Seroprevalencia de hepatitis A en niños y adolescentes en Argentina. Reseñas Infecto Vacunas. 1998; (2):17-25.
30. Verzeri N. Epidemiología de la hepatitis en la Provincia de Buenos Aires. Sistema Provincial de Vigilancia Epidemiológica (SIPROVE). Buenos Aires: Ministerio de Salud de la Provincia de Buenos Aires; 2004.
31. González J, Fay O, Cañero-Velasco C, Fernandez E, Carchio E, Moreiro R, et al. Infección por virus de hepatitis A (HAV) en niños en Argentina: ensayo piloto. Acta Gastroenterol Latinoam. 1997;27(5):331-4.
32. Foussal MD, Picon C, Sorrentino A. Hepatitis A en la infancia. La punta del iceberg infectológico? Acta Gastroenterol Latinoam. 2002; 32(2):101-5.
33. Meyerhoff AS, Jacobs RJ. Transmission of hepatitis A through household contact. J Viral Hepat. 2001;8(6):454-8.
34. Estadísticas Argentina. Vivienda e Infraestructura. Available from: http://www.depeco.econo.unlp.edu.ar/cedlas/arg.htm. Accessed 2 April 2005.
35. United State Department of Health and Human Services, Centers for Disease Control and Prevention. Hepatitis surveillance report no. 57. Atlanta: CDC; 2000.
36. Argentina, Instituto Nacional de Transplantes. Transplante de organos. Available from: http://www.incucai.gov.ar/. Accessed 7 April 2005.
37. Pichon-Riviere A, Regueiro A, Souto A, Augustovski F. Base de datos de costos sanitarios argentinos. Buenos Aires: Instituto de Efectividad Clínica y Sanitaria; Argentina, 2004. (Documento Técnico No. 3.)
38. Hauboldt RH. Cost implications of human organ and tissue transplantations, an update: 1999. Seattle: Milliman & Robertson, Inc.; 1999.
39. Estadísticas Argentina. Salarios, horas trabajadas e ingreso laboral. Available from: http://www.depeco.econo.unlp.edu.ar/cedlas/arg.htm. Accessed 2 April 2005.
40. Dayan GH, Orellana LC, Forlenza R, Ellis A, Chaui J, Kaplan S, et al. La cobertura de la vacunación en niños de 13 a 59 meses de edad en Buenos Aires, Argentina, en 2002. Rev Panam Salud Publica. 2004;16(3):158-67.
41. Feinstone SM, Gust IA. Hepatitis A vaccine. In: Plotkin SA, Orenstein WA eds. Vaccines. 3rd ed. Philadelphia: WB Saunders; 1999. Pp.650-71.
42. Jacobs RJ, Margolis HS, Coleman PJ. The cost-effectiveness of adolescent hepatitis A vaccination in states with the highest disease rates. Arch Pediatr Adol Med. 2000;154(8):763-70.
43. Jacobs RJ, Moleski, RJ, Meyerhoff AS. The value of hepatitis A prevention based on time trade-off and willingness-to-pay measurement. Pharmacoeconomics. 2002;20(11): 739-47.
44. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996;276(15):1253-8.
45. Miller MA, Hinman AR. Cost-benefit and cost-effectiveness analysis of vaccine policy. In: Plotkin SA, Orenstein WA, eds. Vaccines. 3rd ed. Philadelphia: WB Saunders; 1999. Pp. 1074-88.
46. International Monetary Fund. World economic outlook database, September 2005. Available from: http://imf.org/external/pubs/ft/weo/2005/02/data/index. htm. Accessed 20 October 2005.
47. Hadler SC. Global impact of hepatitis A virus infection: changing patterns. In: Hollinger FB, Lemon SM, Margolis HS, eds. Viral hepatitis and liver disease. Baltimore: Williams & Wilkins; 1991. Pp. 14-9.
48. Chodick G, Lerman Y, Wood F, Aloni H, Peled T, Ashkenazi S. Cost-utility analysis of hepatitis A prevention among health-care workers in Israel. J Occup Environ Med. 2002;44(2):109-15.
49. Das A. An economic analysis of different strategies of immunization against hepatitis A virus in developed countries. Hepatology. 1999;29(2):548-52.
50. Samandari T, Bell BP, Armstrong GL. Quantifying the impact of hepatitis A immunization in the United States, 1995-2001. Vaccine. 2004; 22(31-32):4342-50.
51. World Health Organization. WHO position paper on hepatitis A vaccines. Wkly Epidemiol Rec. 2000;75(5):38-44.
52. Van Damme P, Banatvala J, Fay O, Iwarson S, McMahon B, Van Herck K, et al. Hepatitis A booster vaccination: is there a need? Lancet. 2003;362(9389):1065-71.